A prospective study of preemptive tenofovir disoproxil fumarate therapy in HBsAg-positive diffuse large B cell lymphoma patients receiving R-CHOP.

Do Young KimYu Ri KimCheolwon SuhDok Hyun YoonDeok-Hwan YangYong ParkHyeon Seok EomJeong-Ok LeeJae-Yong KwakHye Jin KangShin Young HyunJae-Cheol JoMyung Hee ChangKwai Han YooSung-Nam LimHo-Jin ShinWon Seog KimIn-Ho KimMin Kyung KimHyo Jung KimWon-Sik LeeYeung-Chul MunJin Seok Kim

Published in: The American journal of gastroenterology (2023)

Preemptive TDF therapy in HBsAg-positive patients with DLBCL receiving R-CHOP chemotherapy was safe and effective for preventing HBV-related hepatitis. However, a long-term maintenance strategy of preemptive TDF therapy should be recommended because of the relatively high rate of HBV-related hepatitis after withdrawal from TDF (ClinicalTrials.gov ID: NCT02354846).

Keyphrases

diffuse large b cell lymphoma
hepatitis b virus
epstein barr virus
stem cells
liver failure
squamous cell carcinoma
radiation therapy
mesenchymal stem cells
cell therapy